Astrocyte Pharmaceuticals Inc., a clinical-stage biotechnology company focused on cerebroprotective therapies for concussion, traumatic brain injury, and stroke, has completed a $9.5 million Series B financing round. The new capital will support the continued Phase 2 clinical development of AST-004 and the completion of the STARFAST trial in sports-related concussion. The funding strengthens the company's position as it approaches a critical clinical data milestone.
Series B Financing and Investor Support
The Series B round was led by DeepWork Capital and included continued support from existing investors. New participants included MintPharma Capital, Waterstar Capital, Dynagrow Capital, and Angel Star Ventures. The financing brings total investment in Astrocyte to US$40 million, including funding and grants received to date, and strengthens the balance sheet for upcoming clinical execution.
AST-004 and the STARFAST Trial
AST-004 is a novel cerebroprotective therapy that targets astrocytes, the brain's primary caretaker cells, to enhance their natural ability to protect neurons during metabolic stress after acute injury. The treatment is designed to intervene early in the injury process, shielding vulnerable brain tissue from secondary damage and supporting recovery. This mechanism addresses significant unmet needs in concussion, traumatic brain injury, and acute ischemic stroke.
Enrollment Complete and Data Timeline
Enrollment is now complete in the Phase 2 STARFAST trial, which is evaluating AST-004 in athletes who experience concussion during competitive Australian Rules Football. The randomized, double-blind, placebo-controlled study is assessing safety, objective blood biomarkers of brain injury, and clinical measures of concussion recovery. Topline results are expected this winter.
Clinical Evidence and Future Milestones
AST-004 has completed two Phase 1 clinical safety studies and has advanced into Phase 2 development with support from extensive preclinical data across multiple models of acute brain injury. The program has also received multiple federal research awards that have supported continued development. Following STARFAST, the company expects clinical results from trials in complicated mild traumatic brain injury and acute ischemic stroke to build a comprehensive understanding of the therapy's potential.
Executive Perspective on Clinical Momentum
Chief Executive Officer William Korinek described the current period as one of the most important value inflection points in the company's history. He stated that Astrocyte has built substantial scientific evidence demonstrating AST-004's potential and is now preparing for crucial Phase 2 data from patients. The company expects that results across multiple acute brain injury trials will create a comprehensive clinical profile.
Leadership and Strategic Support
Astrocyte is led by an experienced senior executive team, a world-class scientific and clinical advisory board, and a distinguished board of directors. The company plans to announce a non-clinical advisory board this fall, composed of national leaders in sports, marketing, media, and strategic business operations. These resources are intended to support both clinical advancement and long-term strategic growth.
With the US$9.5 million Series B financing in place, Astrocyte Pharmaceuticals is positioned to advance AST-004 toward crucial Phase 2 data and potential first-in-class approval for concussion and traumatic brain injury. The company's progress in sports-related concussion, complicated mild traumatic brain injury, and acute ischemic stroke underscores a broad cerebroprotective opportunity. Upcoming results from STARFAST will provide important validation of AST-004's ability to protect the brain across multiple acute neurological conditions.